SuperworthTarsus Pharmaceuticals EPS TARS
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$1.09
- Latest quarter, Q2 FY26
- −$0.43
- Fiscal year 2025
- −$1.62
Tarsus Pharmaceuticals' earnings per share was −$1.09 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.43.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.62 | n/a |
| FY2024 | −$3.10 | n/a |
| FY2023 | −$4.59 | n/a |
| FY2022 | −$2.57 | n/a |
| FY2021 | −$0.72 | n/a |
| FY2020 | −$6.37 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.43 | n/a | −$1.09 | |
| Q1 FY26 | −$0.16 | n/a | −$1.14 | |
| Q4 FY25 | −$0.20 | n/a | −$1.62 | |
| Q3 FY25 | −$0.30 | n/a | −$2.02 | |
| Q2 FY25 | −$0.48 | n/a | −$2.33 | |
| Q1 FY25 | −$0.64 | n/a | −$2.73 | |
| Q4 FY24 | −$0.60 | n/a | −$3.10 | |
| Q3 FY24 | −$0.61 | n/a | −$3.76 | |
| Q2 FY24 | −$0.88 | n/a | −$4.43 | |
| Q1 FY24 | −$1.01 | n/a | −$4.72 | |
| Q4 FY23 | −$1.26 | n/a | −$4.59 | |
| Q3 FY23 | −$1.28 | n/a | −$3.84 |
Against its peers
Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TARSTarsus Pharmaceuticals | −$1.09 | |
| ADMAAdma Biologics | $0.70 | −18% a year |
| VCELVericel | $0.46 | +283% a year |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| RGENRepligen | $0.73 | |
| MGTXMeiraGTx | $0.71 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| EXELExelixis | $3.18 | +53% a year |
| INCYIncyte | $7.85 | +78% a year |
| Peer median | $2.17 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Tarsus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.